CCA Summit Live from ASCO 2022

Ghassan K. Abou-Alfa

CCA Summit Live from ASCO 2022

ASCO Highlights

Videos — June 16, 2022

Featuring:

Ghassan K. Abou-Alfa, MD, MBA

Memorial Sloan Kettering Cancer Center
New York, NY

Ghassan Abou-Alfa, MD, MBA, Attending Physician at Memorial Sloan Kettering Cancer Center presents an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2022 annual meeting of the American Society of Clinical Oncology (ASCO). Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.

ASCO Highlights

September 2025, Vol 6, No 3

The ADJUBIL trial reveals that dual immune checkpoint blockade with durvalumab and tremelimumab without capecitabine offers a promising adjuvant therapy option with minimal toxicity for resectable biliary tract cancer.

TP53 Mutations in BTC: A Prognostic Marker and a Potential Target for Immune Checkpoint Inhibitors

ASCO Highlights

September 2025, Vol 6, No 3

Patients with TP53-mutated biliary tract cancer may have poorer prognoses but show enhanced responsiveness to immune checkpoint inhibitors, offering hope for tailored therapeutic strategies.

Triplet Immunotherapy in Advanced Hepatocellular and Biliary Tract Cancers

ASCO Highlights

September 2025, Vol 6, No 3

A novel triplet immunotherapy combining durvalumab, bevacizumab, and tremelimumab shows potential for improving survival in advanced hepatocellular and biliary tract cancers.

Rilvegostomig Plus Chemotherapy in Advanced Biliary Tract Cancer

ASCO Highlights

September 2025, Vol 6, No 3

A novel bispecific antibody, rilvegostomig, combined with chemotherapy shows promising efficacy and safety in improving outcomes for patients with advanced biliary tract cancer.

Zanidatamab-hrii Extends Survival in Previously Treated HER2-Positive BTC

ASCO Highlights

September 2025, Vol 6, No 3

Zanidatamab-hrii significantly improves survival in HER2-positive biliary tract cancer, offering new hope for patients with limited second-line treatment options.

Real-World Outcomes of Ivosidenib in IDH1-Mutated CCA: A Study in US Veterans

ASCO Highlights

September 2025, Vol 6, No 3

Real-world data from US veterans confirm the safety and efficacy of ivosidenib in treating IDH1-mutated cholangiocarcinoma, offering hope for improved outcomes in this challenging cancer.

Initial Findings From a Phase 2 Trial on Trifluridine/Tipiracil Combined With Irinotecan as Second-Line Therapy for CCA

ASCO Highlights

September 2025, Vol 6, No 3

The TRITICC trial highlights a promising second-line therapy with trifluridine, tipiracil, and irinotecan for advanced cholangiocarcinoma, offering hope after failure of first-line treatment.

Advancing Early Detection of BTC Using cfDNA Fragmentomics and Machine Learning

ASCO Highlights

September 2025, Vol 6, No 3

A cutting-edge circulating cell-free DNA fragmentomics approach combined with machine learning offers a noninvasive method for early detection of biliary tract cancer.

Advancing the Fight Against Cholangiocarcinoma: Dr. Ghassan Abou-Alfa on Global Impact and Research Progress

By Ghassan K. Abou-Alfa, MD, MBA

Cholangiocarcinoma

Videos

Dr. Ghassan Abou-Alfa, a renowned medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the global impact of cholangiocarcinoma and the pivotal role of the CCA Summit in driving research, collaboration, and improved patient care.

Results From a Randomized Phase 2 Trial: Addition of SBRT to Systemic Chemotherapy in Locally Advanced CCA (ABC-07)

ASCO Highlights

September 2024, Vol 5, No 3

Efficacy and safety results from the randomized phase 2 ABC-07 trial was presented comparing the addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in patients with locally advanced cholangiocarcinoma (CCA).

CCA Summit Live from ASCO 2022

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

CCA Summit Live from ASCO 2022

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content